Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ACRV Acrivon Therapeutics

Watchlist
12.500
-0.350-2.72%
Close 12/01 16:00 ET
High
12.764
Open
12.520
Turnover
86.19K
Low
12.400
Pre Close
12.850
Volume
6.88K
Market Cap
235.12M
P/E(TTM)
Loss
52wk High
20.703
Shares
18.81M
P/E(Static)
Loss
52wk Low
10.901
Float Cap
73.75M
Bid/Ask %
0.00%
Historical High
20.703
Shs Float
5.90M
Volume Ratio
0.11
Historical Low
10.901
Dividend TTM
--
Div Yield TTM
--
P/B
-6.43
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.12%
Amplitude
2.83%
Avg Price
12.522
Lot Size
0
Float Cap
73.75M
Bid/Ask %
0.00%
Historical High
20.703
Shs Float
5.90M
Volume Ratio
0.11
Historical Low
10.901
Dividend TTM
--
P/B
-6.43
Dividend LFY
--
Turnover Ratio
0.12%
Amplitude
2.83%
Avg Price
12.522
Lot Size
0
Price Forecast

No Data

News

Comment

Company Overview More
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of drug pipeline. Its AP3 is used to generate proprietary OncoSignature companion diagnostics to identify the patients who will benefit from the medicines. The company was founded by Peter Blume-Jensen and Kristina Masson on March 03, 2018 and is headquartered in Watertown, MA.
CEO: Mr. Peter Blume-Jensen, M.D.,PhD
Market: NASDAQ
Listing Date: 11/15/2022
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist